Arena Pharmaceuticals (ARNA) 4.71 $ARNA Vivus'
Post# of 64086
Posted On: 03/16/2015 1:32:02 PM
Arena Pharmaceuticals (ARNA) 4.71 $ARNA
Vivus' Qsymia Breaks 3-Week Stagnancy, Could Start Upward Trend
Clinically Sound Investor - at Seeking Alpha - Mon Mar 16, 8:51AM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Who Will Be Orexigen's Ex-U.S. Partner? My Bet Is On Takeda
Scientist on Stocks - at Seeking Alpha - Mon Mar 16, 7:27AM CDT
OREX: 6.92 (-0.12), ARNA: 4.71 (-0.10)
Orexigen - Contrave Scripts Rise Over 6%, But The Focus Is On Europe
Spencer Osborne - at Seeking Alpha - Sun Mar 15, 7:45PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Too Good to Be True? Proceed With Caution on These 2 Biotechs
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 14, 11:02AM CDT
Tune in to this health care edition of Industry Focus for a look at two small biotechs that sound exciting -- and may in fact prove to be the next big thing -- but which currently face enough challenges that most Fools probably won't want to rush in....
OREX: 6.92 (-0.12), PTLA: 41.44 (+0.74), NVO: 48.89 (+1.29), VVUS: 2.85 (+0.03), SNY: 48.71 (+1.64), MNKD: 5.47 (-0.04), ARNA: 4.71 (-0.10)
Vivus - Qsymia Scripts Pass 11,000 For First Time In 2015
Spencer Osborne - at Seeking Alpha - Fri Mar 13, 4:44PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Arena Pharmaceuticals Now Likely To Miss Q1 Estimates
Clinically Sound Investor - at Seeking Alpha - Fri Mar 13, 3:14PM CDT
ARNA: 4.71 (-0.10)
Arena - Belviq Sales Remain More Modest Than Needed, But A Silver Lining Is Showing
Spencer Osborne - at Seeking Alpha - Fri Mar 13, 3:03PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Orexigen - Stage Is Set For European Approval Decision On Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Fri Mar 13, 9:44AM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Bad News For Pfizer's Chantix May Be Good News For Arena's Belviq
Spencer Osborne - at Seeking Alpha - Thu Mar 12, 4:34PM CDT
PFE: 34.45 (+0.45), ARNA: 4.71 (-0.10)
Orexigen Should Pull Through The Current Bad Publicity
Clinically Sound Investor - at Seeking Alpha - Wed Mar 11, 1:05PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Orexigen - Contrave Sales Continue Up
Spencer Osborne - at Seeking Alpha - Wed Mar 11, 8:34AM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Critical Alerts For Linn Energy, ACADIA Pharmaceuticals, Arena Pharmaceuticals, Sears Holdings and YY Released By InvestorsObserver
PR Newswire - Wed Mar 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LINE, ACAD, ARNA, SHLD and YY.
ACAD: 33.83 (-0.62), YY: 51.49 (-0.30), SHLDZ: 190.00 (+13.50), LINE: 10.66 (-0.54), SHLD: 38.11 (-0.10), ARNA: 4.71 (-0.10)
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
BCS: 15.06 (+0.14), APEI: 32.10 (+0.15), ATRC: 19.60 (-0.13), ATEN: 4.31 (-0.01), ARNA: 4.71 (-0.10)
Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Juno Therapeutics
PR Newswire - Wed Mar 11, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 33.83 (-0.62), HALO: 16.02 (+0.09), GILD: 100.97 (+1.36), JUNO: 52.16 (+2.67), ARNA: 4.71 (-0.10)
Arena Scripts Still Slower Than Needed - Are Downgrades In The Future?
Spencer Osborne - at Seeking Alpha - Wed Mar 11, 7:26AM CDT
ARNA: 4.71 (-0.10)
Type 2 Diabetes Therapeutics Pipeline Review 2015 - Featuring Over 200 Companies
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbq2zb/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 Diabetes Overview - Therapeutics Development - Type 2 Diabetes - Therapeutics under Development by Companies - Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes - Pipeline Products Glance - Type 2 Diabetes - Products under Development by Companies - Type 2 Diabetes - Products under Investigation by Universities/Institutes - Type 2 Diabetes - Companies Involved in Therapeutics Development - Type 2 Diabetes - Therapeutics Assessment - Drug Profiles - Small Molecules to Inhibit CDK5 for Type 2 Diabetes - Drug Profile - Type 2 Diabetes - Recent Pipeline Updates - Type 2 Diabetes - Dormant Projects - Type 2 Diabetes - Discontinued Products - Type 2 Diabetes - Product Development Milestones - Appendix Companies Mentioned - ActogeniX NV - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - AlbireoPharma - Alchemia Limited - Alize Pharma SAS - Allozyne, Inc. - AlphaMab Co., Ltd - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Ardelyx, Inc. - Arena Pharmaceuticals, Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioRestorative Therapies, Inc. For more information visit http://www.researchandmarkets.com/research/jb...2_diabetes
AMBX: (), AZN: 68.87 (+1.52), AMGN: 161.88 (+7.62), BIOD: 1.42 (+0.02), ARNA: 4.71 (-0.10), ARRY: 8.20 (+0.05)
Arena: Belviq's Steady Growth Points To More Total Prescriptions Highs
Clinically Sound Investor - at Seeking Alpha - Tue Mar 10, 2:35PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Does Reading Seeking Alpha Really Help Beat The Market? A 5-Year Meta-Analysis
Force Majeure - at Seeking Alpha - Tue Mar 10, 11:47AM CDT
BOFI: 94.55 (+1.55), NFLX: 418.80 (-19.60), MU: 28.33 (-0.39), TSLA: 192.53 (+3.85), SPY: 207.92 (+2.09), VVUS: 2.85 (+0.03), BIOD: 1.42 (+0.02), ARNA: 4.71 (-0.10)
Novo Nordisk Readies For Saxenda Launch - Investors Need To Keep Expectations Realistic
Spencer Osborne - at Seeking Alpha - Tue Mar 10, 1:21AM CDT
OREX: 6.92 (-0.12), NVO: 48.89 (+1.29), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Arena - Belviq Ads Slow Substantially - Eisai Promises Seem To Be Fading
Spencer Osborne - at Seeking Alpha - Tue Mar 10, 1:07AM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Vivus' Qsymia Breaks 3-Week Stagnancy, Could Start Upward Trend
Clinically Sound Investor - at Seeking Alpha - Mon Mar 16, 8:51AM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Who Will Be Orexigen's Ex-U.S. Partner? My Bet Is On Takeda
Scientist on Stocks - at Seeking Alpha - Mon Mar 16, 7:27AM CDT
OREX: 6.92 (-0.12), ARNA: 4.71 (-0.10)
Orexigen - Contrave Scripts Rise Over 6%, But The Focus Is On Europe
Spencer Osborne - at Seeking Alpha - Sun Mar 15, 7:45PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Too Good to Be True? Proceed With Caution on These 2 Biotechs
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 14, 11:02AM CDT
Tune in to this health care edition of Industry Focus for a look at two small biotechs that sound exciting -- and may in fact prove to be the next big thing -- but which currently face enough challenges that most Fools probably won't want to rush in....
OREX: 6.92 (-0.12), PTLA: 41.44 (+0.74), NVO: 48.89 (+1.29), VVUS: 2.85 (+0.03), SNY: 48.71 (+1.64), MNKD: 5.47 (-0.04), ARNA: 4.71 (-0.10)
Vivus - Qsymia Scripts Pass 11,000 For First Time In 2015
Spencer Osborne - at Seeking Alpha - Fri Mar 13, 4:44PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Arena Pharmaceuticals Now Likely To Miss Q1 Estimates
Clinically Sound Investor - at Seeking Alpha - Fri Mar 13, 3:14PM CDT
ARNA: 4.71 (-0.10)
Arena - Belviq Sales Remain More Modest Than Needed, But A Silver Lining Is Showing
Spencer Osborne - at Seeking Alpha - Fri Mar 13, 3:03PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Orexigen - Stage Is Set For European Approval Decision On Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Fri Mar 13, 9:44AM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Bad News For Pfizer's Chantix May Be Good News For Arena's Belviq
Spencer Osborne - at Seeking Alpha - Thu Mar 12, 4:34PM CDT
PFE: 34.45 (+0.45), ARNA: 4.71 (-0.10)
Orexigen Should Pull Through The Current Bad Publicity
Clinically Sound Investor - at Seeking Alpha - Wed Mar 11, 1:05PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Orexigen - Contrave Sales Continue Up
Spencer Osborne - at Seeking Alpha - Wed Mar 11, 8:34AM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Critical Alerts For Linn Energy, ACADIA Pharmaceuticals, Arena Pharmaceuticals, Sears Holdings and YY Released By InvestorsObserver
PR Newswire - Wed Mar 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LINE, ACAD, ARNA, SHLD and YY.
ACAD: 33.83 (-0.62), YY: 51.49 (-0.30), SHLDZ: 190.00 (+13.50), LINE: 10.66 (-0.54), SHLD: 38.11 (-0.10), ARNA: 4.71 (-0.10)
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
BCS: 15.06 (+0.14), APEI: 32.10 (+0.15), ATRC: 19.60 (-0.13), ATEN: 4.31 (-0.01), ARNA: 4.71 (-0.10)
Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Juno Therapeutics
PR Newswire - Wed Mar 11, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 33.83 (-0.62), HALO: 16.02 (+0.09), GILD: 100.97 (+1.36), JUNO: 52.16 (+2.67), ARNA: 4.71 (-0.10)
Arena Scripts Still Slower Than Needed - Are Downgrades In The Future?
Spencer Osborne - at Seeking Alpha - Wed Mar 11, 7:26AM CDT
ARNA: 4.71 (-0.10)
Type 2 Diabetes Therapeutics Pipeline Review 2015 - Featuring Over 200 Companies
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbq2zb/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 Diabetes Overview - Therapeutics Development - Type 2 Diabetes - Therapeutics under Development by Companies - Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes - Pipeline Products Glance - Type 2 Diabetes - Products under Development by Companies - Type 2 Diabetes - Products under Investigation by Universities/Institutes - Type 2 Diabetes - Companies Involved in Therapeutics Development - Type 2 Diabetes - Therapeutics Assessment - Drug Profiles - Small Molecules to Inhibit CDK5 for Type 2 Diabetes - Drug Profile - Type 2 Diabetes - Recent Pipeline Updates - Type 2 Diabetes - Dormant Projects - Type 2 Diabetes - Discontinued Products - Type 2 Diabetes - Product Development Milestones - Appendix Companies Mentioned - ActogeniX NV - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - AlbireoPharma - Alchemia Limited - Alize Pharma SAS - Allozyne, Inc. - AlphaMab Co., Ltd - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Ardelyx, Inc. - Arena Pharmaceuticals, Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioRestorative Therapies, Inc. For more information visit http://www.researchandmarkets.com/research/jb...2_diabetes
AMBX: (), AZN: 68.87 (+1.52), AMGN: 161.88 (+7.62), BIOD: 1.42 (+0.02), ARNA: 4.71 (-0.10), ARRY: 8.20 (+0.05)
Arena: Belviq's Steady Growth Points To More Total Prescriptions Highs
Clinically Sound Investor - at Seeking Alpha - Tue Mar 10, 2:35PM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Does Reading Seeking Alpha Really Help Beat The Market? A 5-Year Meta-Analysis
Force Majeure - at Seeking Alpha - Tue Mar 10, 11:47AM CDT
BOFI: 94.55 (+1.55), NFLX: 418.80 (-19.60), MU: 28.33 (-0.39), TSLA: 192.53 (+3.85), SPY: 207.92 (+2.09), VVUS: 2.85 (+0.03), BIOD: 1.42 (+0.02), ARNA: 4.71 (-0.10)
Novo Nordisk Readies For Saxenda Launch - Investors Need To Keep Expectations Realistic
Spencer Osborne - at Seeking Alpha - Tue Mar 10, 1:21AM CDT
OREX: 6.92 (-0.12), NVO: 48.89 (+1.29), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
Arena - Belviq Ads Slow Substantially - Eisai Promises Seem To Be Fading
Spencer Osborne - at Seeking Alpha - Tue Mar 10, 1:07AM CDT
OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)
(0)
(0)Scroll down for more posts ▼